Emergence of Chinese Drug Discovery Research: Impact of Hit and Lead Identification

Hughes, 2011, Principles of Early Drug Discovery, Br. J. Pharmacol., 162, 1239, 10.1111/j.1476-5381.2010.01127.x Keseru, 2006, Hit Discovery and Hit-to-Lead Approaches, Drug Discov. Today, 11, 741, 10.1016/j.drudis.2006.06.016 Bartfai, 2006 Wang, 2005, China Evolves from Imitation to Innovation, Drug Discov. Dev., 8, 53 Han, 1994, The Patent System of China—Moving Towards Internationalization, China’s Foreign Trade, 5, 13 Zhang, 2010, Comparison of the New Drug Research and Development Platforms at Home and Abroad: A Preliminary Study, J. Int. Pharm. Res., 37, 170 Qu, 2006, The Construction and Development Strategy of National Drug Innovation System, Chinese J. New Drugs, 15, 1 Sun, 2013, National Science and Technology Major Projects for New Drug Development: A New Engine for China’s Drug Innovation System, Chinese J. New Drugs, 22, 868 The National Center for Drug Screening. http://www.screen.org.cn. Accessed August 18, 2014. Jakobsen, 2011, Innovative Partnerships for Drug Discovery against Neglected Diseases, PLoS Negl. Trop. Dis., 5, e1221, 10.1371/journal.pntd.0001221 Kumar, 2012, High-Throughput Screening and Sensitized Bacteria Identify an M. tuberculosis Dihydrofolate Reductase Inhibitor with Whole Cell Activity, PLoS One, 7, e39961, 10.1371/journal.pone.0039961 The Chinese National Compound Library. http://www.cncl.org.cn. Accessed August 18, 2014. Wu, 2005, Development of a Complex Scintillation Proximity Assay for High-Throughput Screening of PPARgamma Modulators, Acta Pharmacol. Sin., 26, 339, 10.1111/j.1745-7254.2005.00040.x Zhang, 2007, Development of a Homogeneous Calcium Mobilization Assay for High Throughput Screening of Mas-Related Gene Receptor Agonists, Acta Pharmacol. Sin., 28, 125, 10.1111/j.1745-7254.2007.00451.x Yan, 2008, High-Throughput Screening of Novel Antagonists on Melanin-Concentrating Hormone Receptor-1, Acta Pharmacol. Sin., 29, 752, 10.1111/j.1745-7254.2008.00800.x Lee, 2013, Neoclassic Drug Discovery: The Case for Lead Generation Using Phenotypic and Functional Approaches, J Biomol. Screen., 18, 1143, 10.1177/1087057113506118 Zhang, 2007, The Novel Squamosamide Derivative FLZ Protects against 6-Hydroxydopamine-Induced Apoptosis through Inhibition of Related Signal Transduction in SH-SY5Y Cells, Eur. J. Pharmacol., 561, 1, 10.1016/j.ejphar.2006.11.015 Bao, 2014, Squamosamide Derivative FLZ Protected Dopaminergic Neuron by Activating Akt Signaling Pathway in 6-OHDA–Induced In Vivo and In Vitro Parkinson’s Disease Models, Brain Res., 1547, 49, 10.1016/j.brainres.2013.12.026 Zhang, 2009, Validated LC-MS/MS Assay for the Determination of Felbinac: Application to a Preclinical Pharmacokinetics Study of Felbinac Trometamol Injection in Rat, J. Pharm. Biomed. Anal., 50, 41, 10.1016/j.jpba.2009.03.019 Wang, 2009, The Study of Abirritation of a First Type of New Drug, Felbinac Trometamol Injection, Chinese J. Med. Guide, 11, 1327 Xue, 2013, The Discovery of 071031B, a Novel Serotonin and Noradrenaline Reuptake Inhibitor, Neurosci. Lett., 544, 68, 10.1016/j.neulet.2013.02.076 Chen, 2013, Antidepressant-Like Activity of YL-0919: A Novel Combined Selective Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist, PLoS One, 8, e83271, 10.1371/journal.pone.0083271 Sun, 2013, Asymmetric Total Synthesis and Identification of Tetrahydroprotoberberine Derivatives as New Antipsychotic Agents Possessing a Dopamine D(1), D(2) and Serotonin 5-HT(1A) Multi-Action Profile, Bioorg. Med. Chem., 21, 856, 10.1016/j.bmc.2012.12.016 Jia, 2013, Phase I Study on the Pharmacokinetics and Tolerance of ZT-1, a Prodrug of Huperzine A, for the Treatment of Alzheimer’s Disease, Acta Pharmacol. Sin., 34, 976, 10.1038/aps.2013.7 Chen, 2007, A Nonpeptidic Agonist of Glucagon-Like Peptide 1 Receptors with Efficacy in Diabetic db/db Mice, Proc. Natl. Acad. Sci. U. S. A., 104, 943, 10.1073/pnas.0610173104 Su, 2008, Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice, PLoS One, 3, e2892, 10.1371/journal.pone.0002892 He, 2010, Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice, PLoS One, 5, e14205, 10.1371/journal.pone.0014205 Liu, 2012, Cyclobutane Derivatives as Novel Nonpeptidic Small Molecule Agonists of Glucagon-Like Peptide-1 Receptor, J. Med. Chem., 55, 250, 10.1021/jm201150j Lu, 2013, Discovery of Novel Orally Bioavailable GPR40 Agonists, Bioorg Med. Chem. Lett., 23, 2920, 10.1016/j.bmcl.2013.03.060 Yan, 2014, SHR3824, a Novel Selective Inhibitor of Renal Sodium Glucose Cotransporter 2, Exhibits Antidiabetic Efficacy in Rodent Models, Acta Pharmacol. Sin., 35, 613, 10.1038/aps.2013.196 Shu, 2014, Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes, ACS Med. Chem. Lett., 5, 921, 10.1021/ml5001905 Liu, 2012, Acute and Chronic Administration of SHR117887, a Novel and Specific Dipeptidyl Peptidase-4 Inhibitor, Improves Metabolic Control in Diabetic Rodent Models, Acta Pharmacol. Sin., 33, 1013, 10.1038/aps.2012.75 Bu, 2010, Alpha-Glucosidase Inhibition and the In Vivo Hypoglycemic Effect of Butyl-Isobutyl-Phthalate Derived from the Laminaria japonica Rhizoid, Phytother. Res., 24, 1588, 10.1002/ptr.3139 Li, 2006, The PPARalpha/gamma Dual Agonist Chiglitazar Improves Insulin Resistance and Dyslipidemia in MSG Obese Rats, Br. J. Pharmacol., 148, 610, 10.1038/sj.bjp.0706745 Qiu, 2010, High-Throughput Assay for Modulators of Mitochondrial Membrane Potential Identifies a Novel Compound with Beneficial Effects on db/db Mice, Diabetes, 59, 256, 10.2337/db09-0223 Liu, 2011, Kukoamine B, a Novel Dual Inhibitor of LPS and CpG DNA, Is a Potential Candidate for Sepsis Treatment, Br. J. Pharmacol., 162, 1274, 10.1111/j.1476-5381.2010.01114.x Liu, 2011, Dual Targets Guided Screening and Isolation of Kukoamine B as a Novel Natural Anti-Sepsis Agent from traditional Chinese Herb Cortex lycii, Int. Immunopharmacol., 11, 110, 10.1016/j.intimp.2010.10.015 Qiu, 2011, Synthesis and Biological Evaluation of Matijing-Su Derivatives as Potent Anti-HBV Agents, Bioorg. Med. Chem., 19, 5352, 10.1016/j.bmc.2011.08.001 Chen, 2008, Rational Design and Synthesis of 2,2-Bisheterocycle Tandem Derivatives as Non-Nucleoside Hepatitis B Virus Inhibitors, ChemMedChem, 3, 1316, 10.1002/cmdc.200800136 Yang, 2014, Isothiafludine, a Novel Non-Nucleoside Compound, Inhibits Hepatitis B Virus Replication through Blocking Pregenomic RNA Encapsidation, Acta Pharmacol. Sin., 35, 410, 10.1038/aps.2013.175 Liu, 2009, Bicyclol: A Novel Drug for Treating Chronic Viral Hepatitis B and C, Med. Chem., 5, 29, 10.2174/157340609787049316 Chen, 2004, Imrecoxib: A Novel and Selective Cyclooxygenase 2 Inhibitor with Anti-Inflammatory Effect, Acta Pharmacol. Sin., 25, 927 Wu, 2009, Effects of Allisartan, a New AT(1) Receptor Blocker, on Blood Pressure and End-Organ Damage in Hypertensive Animals, Acta Pharmacol. Sin., 30, 307, 10.1038/aps.2009.11 Wang, 2005, A New ATP-Sensitive Potassium Channel Opener Reduces Blood Pressure and Reverses Cardiovascular Remodeling in Experimental Hypertension, J. Pharmacol. Exp. Ther., 312, 1326, 10.1124/jpet.104.078220 Wang, 2004, Targeting Ischemic Stroke with a Novel Opener of ATP-Sensitive Potassium Channels in the Brain, Mol. Pharmacol., 66, 1160, 10.1124/mol.104.003178 Sikka, 2012, Iptakalim: A Novel Multi-Utility Potassium Channel Opener, J. Pharmacol. Pharmacother., 3, 12, 10.4103/0976-500X.92495 Zhang, 2006, 2-(1-Hydroxypentyl)-Benzoate Increases Cerebral Blood Flow and Reduces Infarct Volume in Rats Model of Transient Focal Cerebral Ischemia, J. Pharmacol. Exp. Ther., 317, 973, 10.1124/jpet.105.098517 Zhou, 2010, Treatment of Cerebral Ischemia by Disrupting Ischemia-Induced Interaction of nNOS with PSD-95, Nat. Med., 16, 1439, 10.1038/nm.2245 Zhu, 2013, SMND-309, a Novel Derivative of Salvianolic Acid B, Protects Rat Brains Ischemia and Reperfusion Injury by Targeting the JAK2/STAT3 Pathway, Eur. J. Pharmacol., 714, 23, 10.1016/j.ejphar.2013.05.043 Bai, 2012, Discovery of N-(3,5-bis(1-pyrrolidylmethyl)-4-hydroxybenzyl)-4-methoxybenzenesulfamide (Sulcardine) as a Novel Anti-Arrhythmic Agent, Acta Pharmacol. Sin., 33, 1176, 10.1038/aps.2012.119 Ruan, 2014, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Hyzetimibe (HS-25) in Healthy Chinese Subjects, J. Clin. Pharmacol., 54, 1144, 10.1002/jcph.310 Hu, 2011, Accurate Determination of the Anticancer Prodrug Simmitecan and Its Active Metabolite Chimmitecan in Various Plasma Samples Based on Immediate Deactivation of Blood Carboxylesterases, J. Chromatogr. A, 1218, 6646, 10.1016/j.chroma.2011.07.042 Hu, 2013, Pharmacokinetic Evaluation of the Anticancer Prodrug Simmitecan in Different Experimental Animals, Acta Pharmacol. Sin., 34, 1437, 10.1038/aps.2013.74 Han, 2014, Identification of a Promising PI3K Inhibitor for the Treatment of Multiple Myeloma through the Structural Optimization, J. Hematol. Oncol., 7, 9, 10.1186/1756-8722-7-9 Shi, 2014, A Novel PI3K Inhibitor Displays Potent Preclinical Activity against an Androgen-Independent and PTEN-Deficient Prostate Cancer Model Established from the Cell Line PC3, Toxicol. Lett., 228, 133, 10.1016/j.toxlet.2014.05.003 Zhou, 2010, Synthesis and Biological Evaluation of Novel Triptolide Analogues for Anticancer Activity, Bioorg. Med. Chem. Lett., 20, 6217, 10.1016/j.bmcl.2010.08.106 Xie, 2013, Metabolism and Bioactivation of Famitinib, a Novel Inhibitor of Receptor Tyrosine Kinase, in Cancer Patients, Br. J. Pharmacol., 168, 1687, 10.1111/bph.12047 Chen, 2014, Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study, PLoS One, 9, e95897, 10.1371/journal.pone.0095897 Feng, 1999, Phase II Clinical Study of a New Anticancer Drug Boanmycin [in Chinese], Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 21, 247 Liu, 2012, Formulation and Characterization of Boanmycin-Loaded Liposomes Prepared by pH Gradient Experimental Design, Drug. Deliv., 19, 90, 10.3109/10717544.2011.649217 Xutian, 2009, New Exploration and Understanding of Traditional Chinese Medicine, Am. J. Chin. Med., 37, 411, 10.1142/S0192415X09006941 Zhao, 2012, Analysis and Thinking on Status of Constituent Library of Traditional Chinese Medicines in China [in Chinese], Zhongguo Zhong Yao Za Zhi, 37 Wang, 2007, Biological Screening of Natural Products and Drug Innovation in China, Philos. Trans. R. Soc. Lond. B. Biol. Sci., 362, 1093, 10.1098/rstb.2007.2036 Zhu, 2010, High-Throughput Screening for Bioactive Components from Traditional Chinese Medicine, Comb. Chem. High Throughput Screen., 13, 837, 10.2174/138620710793360257 Harvey, 2008, Natural Products in Drug Discovery, Drug Discov. Today, 13, 894, 10.1016/j.drudis.2008.07.004 Xu, 2006, Bioactive Compounds from Peperomia pellucida, J. Nat. Prod., 69, 247, 10.1021/np050457s Tian, 2005, Stereospecific Induction of Nuclear Factor–kappaB Activation by Isochamaejasmin, Mol. Pharmacol., 68, 1534, 10.1124/mol.105.014720 Zhang, 2007, Bioactive Lignans from Peperomia heyneana, J. Nat. Prod., 70, 662, 10.1021/np0605236 Chinese Clinical Trial Registry. http://www.chictr.org/en/proj/show.aspx?proj=8821. Accessed October 18, 2014. Goodnow, 2006, Hit and Lead Identification: Integrated Technology-Based Approaches, Drug Discov. Today, 3, 367, 10.1016/j.ddtec.2006.12.009 Chinese Academy of Sciences. http://english.cas.cn/ST/LSB/lsb_progress/201204/t20120416_83923.shtml. Accessed October 18, 2014. Hsieh, 2009, Current Prodrug Design for Drug Discovery, Curr. Pharm. Des., 15, 2236, 10.2174/138161209788682523 Ha, 2011, Huperzine A as Potential Treatment of Alzheimer’s Disease: An Assessment on Chemistry, Pharmacology, and Clinical Studies, Chem. Biodivers., 8, 1189, 10.1002/cbdv.201000269 Clinical Update—Debio 9902 (ZT-1) for Alzheimer’s Disease. http://www.drugs.com/clinical_trials/clinical-update-debio-9902-zt-1-alzheimer-s-1241.html. Accessed October 18, 2014. Sriram, 2005, Camptothecin and Its Analogues: A Review on Their Chemotherapeutic Potential, Nat. Prod. Res., 19, 393, 10.1080/14786410412331299005 Huang, 2007, Chimmitecan, a Novel 9-Substituted Camptothecin, with Improved Anticancer Pharmacologic Profiles In Vitro and In Vivo, Clin. Cancer Res., 13, 1298, 10.1158/1078-0432.CCR-06-1277 Jones, 2011, Stroke: Disruption of the nNOS–PSD-95 Complex Is Neuroprotective in Models of Cerebral Ischemia, Nat. Rev. Neurol., 7, 61, 10.1038/nrneurol.2010.203 News from ebiotrade. http://www.ebiotrade.com/newsf/2011-5/2011531173531429.htm. Accessed October 18, 2014. Fredriksson, 2003, The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families: Phylogenetic Analysis, Paralogon Groups, and Fingerprints, Mol. Pharmacol., 63, 1256, 10.1124/mol.63.6.1256 Garland, 2013, Are GPCRs Still a Source of New Targets?, J. Biomol. Screen., 18, 947, 10.1177/1087057113498418 Hollenstein, 2014, Insights into the Structure of Class B GPCRs, Trends Pharmacol. Sci., 35, 12, 10.1016/j.tips.2013.11.001 Heilker, 2009, G-Protein-Coupled Receptor–Focused Drug Discovery Using a Target Class Platform Approach, Drug Discov. Today, 14, 231, 10.1016/j.drudis.2008.11.011 Scott, 2010, Label-Free Whole-Cell Assays: Expanding the Scope of GPCR Screening, Drug Discov. Today, 15, 704, 10.1016/j.drudis.2010.06.008 Williams, 2009, GPCR Signaling: Understanding the Pathway to Successful Drug Discovery, Methods Mol. Biol., 552, 39, 10.1007/978-1-60327-317-6_3 Kirkpatrick, 2012, Predicted Structure of Agonist-Bound Glucagon-Like Peptide 1 Receptor, a Class B G Protein–Coupled Receptor, Proc. Natl. Acad. Sci. U. S. A., 109, 19988, 10.1073/pnas.1218051109 He, 2012, A Continued Saga of Boc5, the First Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist with In Vivo Activities, Acta Pharmacol. Sin., 33, 148, 10.1038/aps.2011.169 Shanghai Institute of Materia Medica. http://www.simm.cas.cn/ydhz/hzdt/201305/t20130515_3840423.html. Accessed August 15, 2014. Institute of Materia Medica, Chinese Academy of Medical Sciences and Perking Union Medical College. http://www.imm.ac.cn/cn/cooperationinfo.asp?rstid=495. Accessed August 18, 2014. Yu, 2014, The Essential Role of TNIK Gene Amplification in Gastric Cancer Growth, Oncogene., 2, e89, 10.1038/oncsis.2014.2 Shen, 2013, Potential Drug Interventions for Diabetic Retinopathy, Drug Discov. Today, 18, 1334, 10.1016/j.drudis.2013.08.018 Qi, 2012, Selective Inhibition of Ezh2 by a Small Molecule Inhibitor Blocks Tumor Cells Proliferation, Proc. Natl. Acad. Sci., 109, 21360, 10.1073/pnas.1210371110 Liu, 2010, Crucial Role of Interleukin-7 in T Helper Type 17 Survival and Expansion in Autoimmune Disease, Nat. Med., 16, 191, 10.1038/nm.2077 Tang, 2014, Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors, J. Med. Chem., 57, 8026, 10.1021/jm5008962 Fei, 2008, A Scalable Synthesis of an Azabicyclooctanyl Derivative, a Novel DPP-4 Inhibitor, J. Org. Chem., 73, 9016, 10.1021/jo801830x Ren, 2012, Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)), J. Med. Chem., 55, 4286, 10.1021/jm2016107 Zhang, 2012, Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models, Clin. Cancer Res., 18, 6658, 10.1158/1078-0432.CCR-12-2694 Zhang, 2013, Small Molecule R1498 as a Well-Tolerated and Orally Active Kinase Inhibitor for Hepatocellular Carcinoma and Gastric Cancer Treatment via Targeting Angiogenesis and Mitosis Pathways, PLoS One, 8, e65264, 10.1371/journal.pone.0065264 Cao, 2014, Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia, Mol. Cell, 53, 247, 10.1016/j.molcel.2013.12.001 Xiao, 2014, Small-Molecule RORgammat Antagonists Inhibit T Helper 17 Cell Transcriptional Network by Divergent Mechanisms, Immunity, 40, 477, 10.1016/j.immuni.2014.04.004 Shanghai Institute of Materia Medica. http://www.simm.cas.cn/gjjl/hzxm/200907/t20090713_2065265.html. Accessed August 20, 2014. Itoh, 2003, Free Fatty Acids Regulate Insulin Secretion from Pancreatic Beta Cells through GPR40, Nature, 422, 173, 10.1038/nature01478 Briscoe, 2003, The Orphan G Protein–Coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids, J. Biol. Chem., 278, 11303, 10.1074/jbc.M211495200 Huang, 2014, Physiology and Therapeutics of the Free Fatty Acid Receptor GPR40, Prog. Mol. Biol. Transl. Sci., 121, 67, 10.1016/B978-0-12-800101-1.00003-X Isaji, 2007, Sodium-Glucose Cotransporter Inhibitors for Diabetes, Curr. Opin. Investig. Drugs, 8, 285 Opie, 2014, Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: New among Antidiabetic Drugs, Cardiovasc. Drugs Ther., 28, 331, 10.1007/s10557-014-6522-0 Altmann, 2004, Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption, Science, 303, 1201, 10.1126/science.1093131 Garcia-Calvo, 2005, The Target of Ezetimibe Is Niemann-Pick C1-Like 1 (NPC1L1), Proc. Natl. Acad. Sci. U. S. A., 102, 8132, 10.1073/pnas.0500269102 Wang, 2013, Discussion on the Transition of Drug R&D Models in China, Prog. Pharmaceut. Sci., 37, 488 Database of Drug Registration and Acceptance. http://db.yaozh.com/zhuce.html. Accessed August 18, 2014.